Key Papers

• Chun YS, Kim MY, Lee SY, Kim MJ, Hong TJ, Jeon JK, Ganbat D, Kim HT, Kim SS, Kam T.-I#, Han S#. (2022) MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's disease. Molecular Psychiatry. 27(11):4770-4780. (#Co-corresponding) (IF:13.437)
• Kam T.-I, Park H, Chou SC, Vranken JGV, Mittenbühler MJ, Kim H, A M, Choi YR, Biswas D, Wang J, Shin Y, Loder A, Karuppagounder SS, Wrann CD, Dawson VL, Spiegelman BM, Dawson TM. (2022) Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin. PNAS. 119(36): e2204835119 (IF:12.777)
• Park HJ*, Kam T.-I*, Peng H, Chou SC, Mehrabani-Tabar AA, Song JJ, Yin X, Karuppagounder SS, Umanah GK, Rao S, Choi Y, Aggarwal A, Chang S, Kim H, Byun J, Liu JO, Dawson TM, Dawson VL (2022) PAAN/MIF Nuclease Inhibition Prevents Neurodegeneration in Parkinson’s Disease. Cell. 185(11):1943-1959.e21 (*Co-first) (IF:66.85)
• Sterling JK*, Kam T.-I*, Guttha S, Park H, Baumann B, Mehrabani-Tabari AA, Schultz H, Anderson B, Alnemri A, Chou SC, Troncoso JC, Dawson VL, Dawson TM, Dunaief J. (2022) Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological α-synuclein. Cell Reports. 38(7):110358 (*Co-first) (IF:9.995)
• Jo A*, Lee Y*, Kam T.-I*, Kang SU, Neifert S, Karuppagounder SS, Khang R, Kang H, Park H, Chou SC, Oh S, Jian H, Swing DA, Ham S, Pirooznia S, Umanah GKE, Mao X, Kumar M, Ko HS, Kang HC, Lee BD, Lee YI, Andrabi SA, Park CH, Lee JY, Kim H, Kim H, Kim H, Cho JW, Paek SH, Na CH, Tessarollo L, Dawson VL, Dawson TM, Shin JH. (2021) PARIS farnesylation prevents neurodegeneration in models of Parkinson’s disease. Science Translational Medicine. 28;13(604):eaax8891 (*Co-first) (IF:19.319)
• Kam T.-I*, Mao X*, Park H*, Chou SC, Karuppagounder SS, Umanah GE, Yun SP, Brahmarchari S, Panicker N, Chen R, Andrabi SA, Qi C, Poirier GG, Pletnikova O, Troncoso JC, Bekris LM, Leverenz JB, Pantelyat A, Ko HS, Rosenthal LS, Dawson TM, Dawson VL. (2018) Poly (ADP-ribose) drives pathologic a-synuclein neurodegeneration in Parkinson’s disease. Science 362(6414), doi: 10.1126/science. aat8407 (*Co-first) (IF: 63.714)
• Yun SP*, Kam T.-I*, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, Kim S, Oh N, Kim NA, Lee S, Brahmachari S, Mao X, Lee JH, Kumar M, An D, Kang SU, Lee Y, Lee KC, Na DH, Kim D, Lee SH, Roschke V, Liddelow SA, Mari Z, Barres BA, Dawson VL, Lee S, Dawson TM, Ko HS. (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nature Medicine 24(7), 931-938 (*Co-first) (IF: 87.241)
• Gwon Y*, Kam T.-I*, Kim SH, Song S, Park H, Lim B, Lee H, Lee W, Jo DG, Jung YK. (2018) TOM1 regulates neuronal accumulation of amyloid-β oligomers by FcγRIIb2 variant in Alzheimer’s disease. Journal of Neuroscience pii:1996-17 (*Co-first) (IF: 6.709)
• Kam T.-I*, Park H*, Gwon Y*, Song S, Kim SH, Moon SW, Jo DG, Jung YK. (2016) FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. Elife pii:e18691 (*Co-first) (IF: 8.140)
• Kam T.-I*, Song S*, Gwon Y, Park H, Yan JJ, Im I, Choi JW, Choi TY, Kim J, Song DK, Takai T, Kim YC, Kim KS, Choi SY, Choi S, Klein WL, Yuan J, and Jung YK. (2013) FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease. Journal of Clinical Investigation 123(7), 2791-2802 (*Co-first) (IF: 19.456)